Sugi Predict

Sugi Predict / Compounds / SCHEMBL203402

SCHEMBL203402

SCHEMBL203402

COc1ccc(Cl)c(C(=O)O)c1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ CA12 O43570 2/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA7 P43166 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ CA14 Q9ULX7 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ GLA P06280 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ RAB9A P51151 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ DPP4 P27487 1/20 0.46
▸ CLCN2 P51788 1/20 0.42
▸ CA4 P22748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18186534 0.86 SMN1; SMN2 (0.47) ALDH1A1KDM4EHSD17B10SMN1; SMN2MEN1
SCHEMBL14855948 0.85 CA12 (0.61) ALDH1A1KDM4EHSD17B10CA12CA1
SCHEMBL202047 0.84 KDM4E (0.46) ALDH1A1KDM4EHSD17B10SMN1; SMN2MEN1
SCHEMBL3057430 0.83 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10CA12CA1
SCHEMBL201405 0.81 LMNA (0.53) ALDH1A1KDM4EHSD17B10CA12CA1
SCHEMBL8564952 0.81 ALDH1A1 (0.61) ALDH1A1KDM4EHSD17B10CA12CA1
SCHEMBL29792549 0.81 LMNA (0.53) ALDH1A1KDM4EHSD17B10CA12CA1
SCHEMBL4404727 0.81 KDM4E (0.45) ALDH1A1KDM4EHSD17B10SMN1; SMN2MEN1
SCHEMBL31193466 0.80 DPP4 (0.60) ALDH1A1KDM4EHSD17B10DPP4TP53
SCHEMBL9385690 0.80 CA2 (0.50) ALDH1A1KDM4EHSD17B10CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 — — US disclosed
EP-2755944-B1 BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2017-06-14 — — EP disclosed
EP-2755944-B1 BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2017-06-14 — — EP disclosed
US-9624159-B2 Aniline derivatives, their preparation and their therapeutic application SANOFI (FR) 2017-04-18 — — US disclosed
US-9624159-B2 Aniline derivatives, their preparation and their therapeutic application SANOFI (FR) 2017-04-18 — — US disclosed
US-20160199330-A1 ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2016-07-14 — — US disclosed
US-9249085-B2 Aniline derivatives, their preparation and their therapeutic application FOVEA PHARMACEUTICALS (FR) 2016-02-02 — — US disclosed
US-9249085-B2 Aniline derivatives, their preparation and their therapeutic application FOVEA PHARMACEUTICALS (FR) 2016-02-02 — — US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-20140350019-A1 ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2014-11-27 — — US disclosed
US-20100022650-A1 Benzamide Derivatives As EP4 Receptor Agonists GLAXO GROUP LIMITED (GB) 2010-01-28 — — US disclosed
EP-2101751-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS Glaxo Group Limited (GB) 2009-09-23 — — EP disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 — — CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 — — EP disclosed
US-20080167377-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2008-07-10 — — US disclosed
US-20080167377-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2008-07-10 — — US disclosed
WO-2008071736-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-06-19 — — WO disclosed
WO-2008071736-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-06-19 — — WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 — — WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167377-A1 Novel compounds F12, C1R, MRGPRX1 ALDH1A1 2581/4885KDM4E 3061/4885HSD17B10 2621/4885
US-20140350019-A1 ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION CYP11B1, CYP11B2, ARG2 ALDH1A1 466/4885KDM4E 3932/4885HSD17B10 456/4885
US-20100022650-A1 Benzamide Derivatives As EP4 Receptor Agonists PTGER4, PTGER1, PTGER3 ALDH1A1 1228/4885KDM4E 1045/4885HSD17B10 4058/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 ALDH1A1 740/4885KDM4E 1251/4885HSD17B10 2650/4885
US-20160199330-A1 ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION CYP11B1, ARG2, CYP11B2 ALDH1A1 497/4885KDM4E 3938/4885HSD17B10 471/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 ALDH1A1 800/4885KDM4E 2407/4885HSD17B10 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.